Document is current

Any future updates will be listed below

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial

Crossref DOI link: https://doi.org/10.1038/s41392-024-01788-2

Published Online: 2024-04-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark